EPISODE · Nov 17, 2023 · 32 MIN
Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate
from Keeping Current CME
What strategies are you using to individualize treatment of HR+/HER2- early breast cancer? Credit available for this activity expires: 11/17/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998210?ecd=bdc_podcast_libsyn_mscpedu
Embed this episode
NOW PLAYING
Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate
0:00
32:14
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Keeping Current CME?
This episode is 32 minutes long.
When was this Keeping Current CME episode published?
This episode was published on November 17, 2023.
Can I download this Keeping Current CME episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!